NASDAQ:MLNT Melinta Therapeutics (MLNT) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free MLNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.35▼$0.5052-Week Range N/AVolumeN/AAverage Volume713,628 shsMarket Capitalization$6.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Melinta Therapeutics alerts: Email Address Ad Porter & CompanyUrgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.Click here now to get what could be the most urgent, and most lucrative research, my team has ever r About Melinta Therapeutics Stock (NASDAQ:MLNT)Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.Read More Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. MLNT Stock News HeadlinesFebruary 28, 2024 | msn.comFDA Requests Additional Data for Venatorx and Melinta's Antibiotic CombinationFebruary 27, 2024 | msn.comPromising Phase 3 Results for Cefepime-Taniborbactam in Treating Complicated UTIsMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 23, 2024 | finance.yahoo.comVenatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-TaniborbactamDecember 5, 2023 | msn.comCidara, Melinta announce publication of Rezzayo data in medical journalNovember 9, 2023 | finance.yahoo.comMelinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.October 11, 2023 | finance.yahoo.comMelinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023October 2, 2023 | uk.finance.yahoo.comMelinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO™ (rezafungin for injection)March 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:September 26, 2023 | thestreet.comMelinta Therapeutics, Inc.May 15, 2023 | finance.yahoo.comMelinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in CanadaMarch 1, 2023 | seekingalpha.comCidara Therapeutics Sheds Skin, Shifts To ImmunotherapyFebruary 24, 2023 | finance.yahoo.comBiVictriX Therapeutics reports "really exciting" BCX001 dataOctober 20, 2022 | technews.tmcnet.comOptimizeRx and Melinta Therapeutics Present Third Annual Innovate4Outcomes(R) Healthcare Design Thinking-Inspired EventJuly 27, 2022 | finance.yahoo.comMelinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.October 25, 2021 | finance.yahoo.comMelinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug DevelopmentSeptember 20, 2021 | apnews.comMelinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)See More Headlines Receive MLNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2019Today3/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MLNT CUSIP15130J10 CIK1461993 Webwww.melinta.com Phone908-617-1309FaxN/AEmployees290Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($17.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-157,190,000.00 Net Margins-393.39% Pretax MarginN/A Return on Equity-101.29% Return on Assets-28.68% Debt Debt-to-Equity Ratio1.11 Current Ratio1.03 Quick Ratio0.72 Sales & Book Value Annual Sales$96.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$16.96 per share Price / BookN/AMiscellaneous Outstanding Shares13,750,000Free FloatN/AMarket Cap$6.88 million OptionableOptionable Beta4.16 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Erin M. Duffy (Age 51)Chief Scientific Officer & Exec. VP Mr. John H. Johnson (Age 61)CEO & Director Dr. Thomas A. SteitzCo-FounderDr. Peter B. Moore Ph.D.Co-FounderDr. William L. JorgensenCo-FounderKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXShuttle PharmaceuticalsNASDAQ:SHPHBright Minds BiosciencesNASDAQ:DRUGAlterity TherapeuticsNASDAQ:ATHEGT BiopharmaNASDAQ:GTBPView All Competitors MLNT Stock Analysis - Frequently Asked Questions How were Melinta Therapeutics' earnings last quarter? Melinta Therapeutics Inc (NASDAQ:MLNT) announced its earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by $13.12. The biotechnology company had revenue of $15.87 million for the quarter, compared to analysts' expectations of $15.51 million. Melinta Therapeutics had a negative net margin of 393.39% and a negative trailing twelve-month return on equity of 101.29%. When did Melinta Therapeutics' stock split? Melinta Therapeutics's stock reverse split before market open on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Melinta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), NVIDIA (NVDA), Novavax (NVAX) and Nabriva Therapeutics (NBRV). This page (NASDAQ:MLNT) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Melinta Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.